Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRIMAD: Postoperative Reintroduction of FOLFIRI-Based Chemotherapy After Resection of Colorectal Liver Metastases
2023-504831-42-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of irinotecan in colorectal cancer (CRC) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Disease-free survival rate at 3 years. Planned start Jun 2025; status: authorised.
02
Drugs
irinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2023-504831-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504831-42-00.